Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration

Atherosclerosis

Volumn 202, Issue 1, 2009, Pages 34-40

  Shiraya, Suguru ^a,b   Miyake, Takashi ^a   Aoki, Motokuni ^c   Yoshikazu, Fujiwara ^a,b   Ohgi, Shigetsugu ^b   Nishimura, Motonobu ^b   Ogihara, Toshio ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c MORINOMIYA UNIVERSITY OF MEDICAL SCIENCES   (Japan)

Author keywords

Abdominal aortic aneurysm; Collagen; ICAM; Macrophage; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; COLLAGEN; ELASTASE; ELASTIN; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE ELASTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMELYSIN;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG MEGADOSE; MACROPHAGE MIGRATION INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE SECTION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTIC ANEURYSM, ABDOMINAL; CELL MOVEMENT; COLLAGEN; DISEASE MODELS, ANIMAL; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MACROPHAGES; PANCREATIC ELASTASE; PYRROLES; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 57649200495     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.03.020     Document Type: Article

References (28)

1. Almuti K., Rimawi R., Spevack D., and Ostfeld R.J. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 109 (2006) 7-15
2. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
3. Jukema J.W., Bruschke A.V., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91 (1995) 2528-2540
4. Pfeffer M.A., Sacks F.M., Moye L.A., et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 76 (1995) 98C-106C
5. Van der Vliet J.A., and Boll A.P.M. Abdominal aortic aneurysm [seminar]. Lancet 349 (1997) 863-866
6. Collin J. The epidemiology of abdominal aortic aneurysm. Br J Hosp Med 40 (1988) 65-68
7. Norrgard O., Angquist K.A., and Johnson O. Familial aortic aneurysms: serum concentrations of triglyceride, cholesterol, HDL-cholesterol and (VSLD + LDL)-cholesterol. Br J Surg 72 (1985) 113-116
8. Petrinec D., Liao S., Holmes D.R., et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kDa gelatinase. J Vasc Surg 23 (1996) 336-346
9. Zhang L., Zhang Z.G., Ding G.L., et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 112 (2005) 3486-3494
10. Hobbs S.D., Claridge M.W., Quick C.R., et al. LDL cholesterol is associated with small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 26 December (6) (2003) 618-622
11. Leurs L.J., Visser P., Laheij R.J., et al. Statin use is associated with reduced all-cause mortality after endovascular abdominal aortic aneurysm repair. Vascular 14 (2006) 1-8
12. Schouten O., van Laanen J.H., Boersma E., et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 32 (2006) 21-26
13. Newman K.M., Jean-Claude J., Hong L., Ramey W.G., and Tilson M.D. Cytokines that activate proteolysis are elevated in abdominal aortic aneurysm. Circulation 90 (1994) 224-227
14. Shah P.K. Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation 96 (1997) 2115-2117
15. Nakashima H., Aoki M., Miyake T., et al. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of nuclear factor kappaB and ets transcription factors. Circulation 109 (2004) 132-138
16. Miyake T., Aoki M., Nakashima H., et al. Prevention of abdominal aortic aneurysms by simultaneous inhibition of NFkappaB and ets using chimeric decoy oligonucleotides in a rabbit model. Gene Ther 13 (2006) 695-704
17. Liu M., Sun H., Wang X., et al. Association of increased expression of macrophage elastase (matrix metalloproteinase 12) with rheumatoid arthritis. Arthritis Rheum 50 (2004) 3112-3117
18. Curci J.A., Liao S., Huffman M.D., Shapiro S.D., and Thompson R.W. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest 102 (1998) 1900-1910
19. Longo G.M., Buda S.J., Fiotta N., et al. MMP-12 has a role in abdominal aortic aneurysms in mice. Surgery 137 (2005) 457-462
20. Sho E., Sho M., Hoshina K., et al. Hemodynamic forces regulate mural macrophage infiltration in experimental aortic aneurysms. Exp Mol Pathol 76 (2004) 108-116
21. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
22. Kolyada A.Y., Fedtsov A., and Madias N.E. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells. Hypertension 38 (2001) 1024-1029
23. Novitskiy G., Potter J.J., Rennie-Tankersley L., and Mezey E. Identification of a novel NF-kappaB-binding site with regulation of the murine alpha2(I) collagen promoter. J Biol Chem 9 279 (2004) 15639-15644
24. Seguin C.A., and Bernier S.M. TNFalpha suppresses link protein and type II collagen expression in chondrocytes: role of MEK1/2 and NF-kappaB signaling pathways. J Cell Physiol 197 (2003) 356-369
25. Steinmetz E.F., Buckley C., Shames M.L., et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 241 (2005) 92-101
26. Kalyanasundaram A., Elmore J.R., Manazer J.R., et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 43 (2006) 117-124
27. Nagashima H., Aoka Y., Sakomura Y., et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 36 (2002) 158-163
28. Waehre T., Damas J.K., Gullestad L., et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 41 (2003) 1460-1467